阿維A酸市場機會、成長要素、產業趨勢分析及2026年至2035年預測

2025 年全球阿維A酸市場價值為 3,660 萬美元，預計到 2035 年將達到 5,920 萬美元，年複合成長率為 5%。

銀屑病市場擴張的促進因素包括多個地區銀屑病患病率的上升，以及診斷工具的改進和人口結構的變化。隨著更多患者得到早期診斷，對能夠提供長期症狀管理的系統性療法的需求持續成長。這一趨勢在高所得國家尤為顯著，這些國家的銀屑病終生患病率不斷上升，皮膚科醫療基礎設施也在不斷完善。全球銀屑病負擔的加重直接推動了對阿維A酸的穩定且持續的需求。此外，人們對銀屑病及其廣泛健康影響的認知不斷提高，促進了早期診斷和適當治療。國際社會所進行的公眾和政策制定者教育工作有助於減少社會歧視，提高醫療服務的可近性，進而提高已開發市場和新興市場的乾癬檢出率。這些因素共同為市場的長期成長奠定了堅實的基礎。

預計到2025年，非專利阿維A酸市場規模將達到1,880萬美元。學名藥必須符合嚴格的監管標準，並證明其與原廠藥具有生物等效性，從而確保其安全性和有效性相當。憑藉數十年的臨床經驗，學名藥無需進行大量的重複試驗，因此具有很高的成本效益和廣泛的可及性。這種價格優勢和可近性深受臨床醫生、支付方和患者的青睞，尤其是在對價格敏感的醫療保健體系中，從而保證了學名藥的廣泛應用。

預計到2025年，25毫克劑量組的市場規模將達到1,730萬美元。此劑量可進行精確的劑量調整，從而在最佳化療效的同時最大限度地減少副作用。較低的劑量可以提高患者的耐受性，減少不良反應，並有助於長期堅持用藥，這對於銀屑病的持續治療至關重要。

預計2025年，美國阿維A酸市場規模將達1,370萬美元。銀屑病的高發病率以及對有效系統性治療的需求是推動成長要素。對於因禁忌症、費用或缺乏非免疫抑制療法而無法使用生物製藥的患者而言，阿維A酸尤其重要。廣泛的診斷手段、沉重的疾病負擔以及持續的治療需求，共同支撐著美國市場的發展。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 全球銀屑病患者數量呈上升趨勢
    • 治療方法進展
    • 提高認知和診斷水平
    • 皮膚科診所數量增加
  • 產業潛在風險與挑戰
    • 嚴格的監管要求
    • 對副作用和安全性的擔憂
  • 市場機遇
    • 對生物製藥。
• 成長潛力分析
• 監理情勢
  • 北美洲
  • 歐洲
• 科技趨勢
  • 當前技術趨勢
  • 新興技術
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 公司矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 合作夥伴關係和合資企業
  • 新產品發布
  • 擴張計劃

第5章 市場估算與預測：依產品類型分類，2022-2035年

• 品牌商品
• 學名藥

第6章 市場估計與預測：依劑型分類，2022-2035年

• 10 mg
• 25mg
• 50mg

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 銀屑病
• 魚鱗病
• 達裡爾氏症
• 毛髮紅皮症
• 固態器官移植
• 格洛弗病
• 扁平苔癬
• 紅斑狼瘡

第8章 市場估算與預測：依通路分類，2022-2035年

• 醫院藥房
• 網路藥房
• 零售藥房

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Amneal Pharmaceuticals, Inc.
• Biophore
• Chongqing Huapont Pharmaceutical Co., Ltd.
• Glenmark Pharmaceuticals Ltd.
• GSK Plc
• Merck KGaA
• Prasco Laboratories
• Sun Pharma Industries Limited
• Teva Pharmaceuticals Industries Ltd
• Alembic Pharmaceuticals Ltd

The Global Acitretin Market was valued at USD 36.6 million in 2025 and is estimated to grow at a CAGR of 5% to reach USD 59.2 million by 2035.

The market's expansion is fueled by the rising prevalence of psoriasis across multiple regions, supported by better diagnostic tools and shifting population demographics. As more patients are diagnosed earlier, the need for systemic therapies that offer long-term symptom management continues to grow. This trend is particularly prominent in high-income countries where lifetime prevalence rates are increasing, as well as in regions enhancing dermatological infrastructure. The growing global burden of psoriasis directly drives steady, sustained demand for acitretin. Furthermore, heightened awareness about psoriasis and its broader health implications is promoting early diagnosis and timely treatment. International initiatives aimed at educating the public and policymakers are helping reduce stigma and encourage medical consultation, increasing detection rates in both developed and emerging markets. Together, these factors are establishing a strong foundation for the market's long-term growth.

The generic acitretin segment accounted for USD 18.8 million in 2025. Generic products follow strict regulatory standards and must demonstrate bioequivalence to the reference drug, ensuring comparable safety and efficacy. With decades of clinical knowledge, generics do not require extensive repeat trials, making them highly cost-effective and widely accessible. This affordability and availability appeal to clinicians, payers, and patients, particularly in price-sensitive healthcare systems, ensuring broad adoption.

The 25 mg segment reached USD 17.3 million in 2025. This strength allows precise dose titration to optimize efficacy while minimizing side effects. Lower doses improve patient tolerance, reduce adverse effects, and support long-term adherence, which is critical for sustained psoriasis management.

U.S. Acitretin Market reached USD 13.7 million in 2025. High psoriasis prevalence and the need for effective systemic therapies are key growth drivers. Acitretin is particularly important for patients who cannot use biologic treatments due to contraindications, cost, or preference for non-immunosuppressive therapies. The combination of widespread diagnosis, significant disease burden, and ongoing treatment requirements continues to support the U.S. market.

Key companies in the Global Acitretin Market include Biophore, Teva Pharmaceuticals Industries Ltd, Glenmark Pharmaceuticals Ltd, Sun Pharma Industries Limited, GSK Plc, Alembic Pharmaceuticals Ltd, Amneal Pharmaceuticals, Inc., Merck KGaA, Chongqing Huapont Pharmaceutical Co., Ltd., and Prasco Laboratories. Market players are strengthening their presence by expanding generic and branded product portfolios, investing in R&D for improved formulations, and focusing on bioequivalence and safety validation to gain regulatory approval. Companies are pursuing strategic collaborations with distributors and healthcare providers to enhance market penetration and accessibility. Pricing strategies, patient assistance programs, and education initiatives for clinicians and patients are used to drive adoption. Additionally, firms leverage digital platforms to increase awareness of psoriasis management and promote treatment adherence, while investing in emerging markets to capture underserved patient populations and sustain long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Product type trends
  • 2.2.2 Dosage strength trends
  • 2.2.3 Application trends
  • 2.2.4 Distribution channel trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of psoriasis globally
    • 3.2.1.2 Advancements in treatment
    • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.1.4 Growing dermatology specialty clinics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Side effects and safety concerns
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising demand for cost-effective alternatives to biologics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Branded
• 5.3 Generics

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 10 mg
• 6.3 25 mg
• 6.4 50 mg

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Psoriasis
• 7.3 Ichthyosis
• 7.4 Darier disease
• 7.5 Pityriasis rubra pilaris
• 7.6 Solid organ transplants
• 7.7 Grover’s disease
• 7.8 Lichen planus
• 7.9 Lupus erythematosus

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Online pharmacies
• 8.4 Retail pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 1.1.1 U.S.
  • 1.1.2 Canada
• 9.3 Europe
  • 1.1.3 Germany
  • 1.1.4 UK
  • 1.1.5 France
  • 1.1.6 Spain
  • 1.1.7 Italy
  • 1.1.8 Netherlands
• 9.4 Asia Pacific
  • 1.1.9 China
  • 1.1.10 Japan
  • 1.1.11 India
  • 1.1.12 Australia
  • 1.1.13 South Korea
• 9.5 Latin America
  • 1.1.14 Brazil
  • 1.1.15 Mexico
  • 1.1.16 Argentina
• 9.6 Middle East and Africa
  • 1.1.17 South Africa
  • 1.1.18 Saudi Arabia
  • 1.1.19 UAE

Chapter 10 Company Profiles

• 10.1 Amneal Pharmaceuticals, Inc.
• 10.2 Biophore
• 10.3 Chongqing Huapont Pharmaceutical Co., Ltd.
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 GSK Plc
• 10.6 Merck KGaA
• 10.7 Prasco Laboratories
• 10.8 Sun Pharma Industries Limited
• 10.9 Teva Pharmaceuticals Industries Ltd
• 10.10 Alembic Pharmaceuticals Ltd